
NRIX Stock Forecast & Price Target
NRIX Analyst Ratings
Bulls say
Nurix Therapeutics is a promising biopharmaceutical company with a strong integrated discovery platform that has the potential to bring targeted protein degradation therapies for cancer and inflammatory diseases to market. Their pipeline includes multiple drug candidates that have shown promising preclinical and clinical results, and their unique approach to targeting specific proteins sets them apart from competitors in the industry. Despite the company's current net loss and need for additional funding, their collaborations and milestone payments provide potential for future financial growth. Based on their innovative platform and promising pipeline, Nurix Therapeutics has a positive outlook for investors.
Bears say
Nurix Therapeutics is a biopharmaceutical company with potential in CNS-involved tumors due to positive preclinical data on its drug candidates. However, the company is still in the early stages of clinical development, and its financials only reflect collaboration revenues and cash on hand. The recent interest from major pharma companies in novel degrader-antibody conjugates, like those being developed by Nurix, may be a positive sign but it is still too early to accurately predict the success of these programs.
This aggregate rating is based on analysts' research of Nurix Therapeutics, Inc and is not a guaranteed prediction by Public.com or investment advice.
NRIX Analyst Forecast & Price Prediction
Start investing in NRIX
Order type
Buy in
Order amount
Est. shares
0 shares